To the full analysis
BeOne Medicines stock: growth
ONCBeOne Medicines reported $5.34B in revenue for fiscal 2025, up 40.2% on the prior year, up 76.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
67.3%
per year from 2013 to 2025, per share 29.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
58.3%
per year from 2013 to 2025, per share 23%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 76.8% | 89.8% | 67.3% |
| Revenue per share | 67.6% | 67.6% | 29.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | 58.3% |
| Free cash flow per share | no data | no data | 23.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $11.15M | −$7.49M | $3.81M |
| 2014 | $13.04M | −$18.28M | −$9.35M |
| 2015 | $8.82M | −$57.1M | −$45.16M |
| 2016 | $1.07M | −$119.22M | −$113.02M |
| 2017 | $238.39M | −$93.11M | −$45.98M |
| 2018 | $198.22M | −$673.77M | −$688.55M |
| 2019 | $428.21M | −$948.63M | −$908.88M |
| 2020 | $308.87M | −$1.62B | −$1.51B |
| 2021 | $1.18B | −$1.46B | −$1.61B |
| 2022 | $1.42B | −$2B | −$1.97B |
| 2023 | $2.46B | −$881.71M | −$1.75B |
| 2024 | $3.81B | −$644.79M | −$669.77M |
| 2025 | $5.34B | $286.93M | $941.74M |
Revenue by region
Where BeOne Medicines AG generates its revenue.
- United States$2.9B54%
- China$1.7B31%
- Europe$611.4M11%
- Other$171.8M3%
“Other” combines smaller regions with revenue the company does not assign to a region. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $2.88B | 53.9% |
| China | $1.68B | 31.4% |
| Europe | $611.37M | 11.4% |
| Other | $171.81M | 3.2% |
| Total revenue | $5.34B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 8 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.